CalbaTech's new subsidiary, TherapyStem, Inc., has created a patent-pending., process to harvest stem cells from HIV infected individuals to be cryopreserved for future transplantation into a client for medical purposes. All other stem cell collection services exclude the collection, processing and storage of blood from individuals with HIV. As the business of TherapyStem develops, the company also believes that it will be able to collect, process and store stem cells from umbilical cords that have come from a mother that has HIV. Those cords are currently excluded from collection by cord blood companies.
Sue MacLeman Rudi Michelson
Chief Executive Officer Monsoon Communications
+61 437 211 200 +61 411 402 737
Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with City of Hope in Duarte, California, is currently in Phase I trial at City of Hope. For additional information, please visit http://www.benitec.com.
E & E Communications
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences
company (http://www.CalbaTech.com) concentrating on providing products and
platforms to the research market for biotech and pharmaceutic
|SOURCE Benitec Limited; CalbaTech, Inc.|
Copyright©2007 PR Newswire.